Deutsche Bank AG Invests $143.07 Million in IQVIA Holdings Inc. $IQV

Deutsche Bank AG acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, Holdings Channel reports. The fund acquired 740,473 shares of the medical research company’s stock, valued at approximately $143,074,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. Financial Freedom LLC acquired a new position in IQVIA in the 1st quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new position in IQVIA during the 1st quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new stake in IQVIA during the 4th quarter valued at $27,000. Gilpin Wealth Management LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at $27,000. Finally, CrossGen Wealth LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at $28,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Up 4.0%

NYSE:IQV opened at $249.62 on Thursday. The company’s 50 day moving average is $210.23 and its 200-day moving average is $186.82. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $251.36. The firm has a market cap of $41.09 billion, a price-to-earnings ratio of 30.97, a P/E/G ratio of 2.04 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has authorized a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock worth $3,098,793 in the last three months. 1.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on IQV. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. TD Cowen raised their price target on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research report on Tuesday, July 28th. Finally, William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.